Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

RNasin® Ribonuclease Inhibitor, Recombinant Protocol

Instructions for Use of Product(s)
N2511, N2515

Literature # 9PIN251

RNasin® Ribonuclease Inhibitor has broad-spectrum RNase inhibitory properties. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at a 1:1 ratio. The Ki value for the binding of RNasin® Ribonuclease Inhibitor to RNase (e.g., RNase A) is approximately 10–14M. Promega offers two different preparations: Natural RNasin® Ribonuclease Inhibitor (Cat.# N2111) and Recombinant RNasin® Ribonuclease Inhibitor (Cat.# N2511, N2515). All of these products are purified using a combination of ion exchange and affinity chromatography, and Natural and Recombinant RNasin® Ribonuclease Inhibitors are devoid of DNA exonuclease and endonuclease activity and RNase activity. In addition to its ability to inhibit RNase activity, RNasin® Ribonuclease Inhibitor has been shown to inhibit angiogenesis induced by angiogenin, basic fibroblast growth factor (bFGF) and sodium orthovanadate. Moreover, RNasin® Ribonuclease Inhibitor reduced neovascularization evoked by implanted tumor cells and significantly inhibited tumor growth in a murine model.

Printed in USA. Revised 4/18